Prior art

ClearForce Awarded U.S. Patent for Continuous Employee Risk Monitoring Technology

Retrieved on: 
Thursday, May 2, 2024
Public sector, National security advisor, Risk, Bias, Safety, HR, Theft, Triage, United States Marine Corps, Workplace, LexisNexis, Transport, EEOC, API, Risk management, Violence, Patent, Prior art, Organization, Privacy, SAFETY, System, Security, Government, FCRA, Fraud

VIENNA, Va., May 2, 2024 /PRNewswire/ -- ClearForce, an analytics and risk technology leader in the early and ongoing discovery of employee risk, announced today that it has been awarded US Patent No. 11,961,029 for Systems & Methods for Electronically Monitoring Employees to Determine Potential Risk. ClearForce commercializes its patent through its Resolve™ platform that synthesizes employee risk signals and alerts from many diverse data sources into a unified platform for triage, investigation and analytics. By incorporating criminal, legal, financial, social, internal incident and network activity data, ClearForce provides a holistic view of potential employee risks, allowing for rapid detection and mitigation. ClearForce's innovation includes unique controls for initial anonymity, privacy and legal compliance.

Key Points: 
  • VIENNA, Va., May 2, 2024 /PRNewswire/ -- ClearForce, an analytics and risk technology leader in the early and ongoing discovery of employee risk, announced today that it has been awarded US Patent No.
  • ClearForce commercializes its patent through its Resolve™ platform that synthesizes employee risk signals and alerts from many diverse data sources into a unified platform for triage, investigation and analytics.
  • "ClearForce delivers a paradigm shift in how organizations approach employee risk management, helping them move from a reactive to a proactive model," said Tom Miller, CEO of ClearForce.
  • ClearForce technology is utilized for mission critical risk programs such as continuous evaluation, insider threat, security, safety, post-hire screening, trusted workforce, SAFETY Act and suicide prevention.

Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®

Retrieved on: 
Wednesday, January 31, 2024
Patent, EVP, Trade, Bausch & Lomb, NOS, Latanoprostene bunod, United States patent law, Prior art, Pharmaceutical industry

Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®

Key Points: 
  • Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has determined that U.S. Patent No.
  • 7,629,345, which covers latanoprostene bunod, commercialized by Bausch + Lomb under the trademark VYZULTA®, is eligible for patent term extension of five years.
  • Nicox has also applied for patent term extension of two other patents covering latanoprostene bunod, U.S. patent Nos.
  • Nicox, in collaboration with Bausch + Lomb, must now elect which patent will be the subject of the patent term extension, and, depending on the choice of the patent, this may lead to an extension to either 2029 or 2030.

Sterne Kessler Elects Six New Directors in 2024

Retrieved on: 
Thursday, January 4, 2024
Biology, Senior counsel, Auburn University, Brooklyn Law School, Prior art, Intellectual property, Science, Blockchain, University, Biotechnology, Software, Glass, Research, Physics, Supreme court, Patent, Pennsylvania State University, George Mason University, Freedom, Supreme, Chase, Biochemistry, Data compression, Artificial intelligence, Texas A&M University, Smartphone, Engineering, George, State university system, Lawyer, Virginia Tech, Synthetic biology, PTAB, Information technology, ITC, Pharmaceutical industry

WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox is proud to announce that six attorneys have been elected to the directorship effective January 1, 2024.

Key Points: 
  • WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox is proud to announce that six attorneys have been elected to the directorship effective January 1, 2024.
  • "It is an honor to congratulate our six new directors on this well-deserved milestone.
  • Read more about Sterne Kessler's new directors:
    David W. Haars , is a member of Sterne Kessler's Electronics Practice Group.
  • He regularly represents both complainants and respondents across a wide range of technologies in Section 337 investigations before the ITC.

Sports Data Labs, Inc. Announces Issuance of New U.S. Patent Covering its Novel Generative AI-Based Method for Creating Synthetic Data to Replace Missing and Outlier Data Values

Retrieved on: 
Tuesday, January 2, 2024
Technology, Health Technology, General Sports, Other Science, Artificial Intelligence, Research, Medical Devices, Professional Services, Health, Wearables, Mobile Technology, General Health, Nanotechnology, Science, Other Technology, Software, Hardware, Electronic Design Automation, Sports, Data Management, Patent Law, Consumer Electronics, Other Health, Biometrics, Prior art, ECG, Multimedia, Athlete, Collection, Heart rate, Biomarker, Patent, Sensor, AI, Sport, Insurance, Intelligence, United States patent law, Pharmaceutical industry

11,850,053 to the company covering a novel system and method for calculating accurate, real-time heart rate (HR) measurements from high sampling, electrocardiogram (ECG)-based sensors.

Key Points: 
  • 11,850,053 to the company covering a novel system and method for calculating accurate, real-time heart rate (HR) measurements from high sampling, electrocardiogram (ECG)-based sensors.
  • SD Labs’ issued patent, entitled “A System and Method for Measuring Heart Rate,” also covers a novel method for detecting and replacing missing and outlier sensor-based data values with artificial (i.e., synthetic) data.
  • The issued patent also covers an AI-based method for generating predictive artificial data values for any missing or outlier values within a sensor-based data set, which can be applicable to all types of biological sensor data regardless of sensor type.
  • “Our synthetic data generator enables more complete data sets to be created, a requisite for AI systems to be more effective in analyzing and creating value with data.

Four Steps Telcos Must Take to Transform into Techcos to Capture Untapped Enterprise 5G Returns and Combat Revenue Decline

Retrieved on: 
Wednesday, December 13, 2023
SEP, Research, Senior, 3GPP, Prior art

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- According to global technology intelligence firm ABI Research, diminishing revenues, a growing consumer demand for digital services, and a lucrative but underserved enterprise market mean that traditional telcos can no longer afford to be merely connectivity providers. They must transition to becoming technology companies (techcos) to survive. In its latest whitepaper, How Telcos Can Transform into Techcos, based on exclusive research and extensive interviews across the industry, ABI Research provides a four-step process for telcos to successfully make the techco transition.

Key Points: 
  • They must transition to becoming technology companies (techcos) to survive.
  • In its latest whitepaper, How Telcos Can Transform into Techcos , based on exclusive research and extensive interviews across the industry, ABI Research provides a four-step process for telcos to successfully make the techco transition.
  • ABI Research sees a clear signal for mobile operators to increasingly deploy automated solutions to streamline operations, optimize resource allocation, and drive cost efficiencies.
  • The whitepaper details a four-step process that telcos can use to traverse the telco-to-techco journey.

Four Steps Telcos Must Take to Transform into Techcos to Capture Untapped Enterprise 5G Returns and Combat Revenue Decline

Retrieved on: 
Wednesday, December 13, 2023
SEP, Research, Senior, 3GPP, Prior art

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- According to global technology intelligence firm ABI Research, diminishing revenues, a growing consumer demand for digital services, and a lucrative but underserved enterprise market mean that traditional telcos can no longer afford to be merely connectivity providers. They must transition to becoming technology companies (techcos) to survive. In its latest whitepaper, How Telcos Can Transform into Techcos, based on exclusive research and extensive interviews across the industry, ABI Research provides a four-step process for telcos to successfully make the techco transition.

Key Points: 
  • They must transition to becoming technology companies (techcos) to survive.
  • In its latest whitepaper, How Telcos Can Transform into Techcos , based on exclusive research and extensive interviews across the industry, ABI Research provides a four-step process for telcos to successfully make the techco transition.
  • ABI Research sees a clear signal for mobile operators to increasingly deploy automated solutions to streamline operations, optimize resource allocation, and drive cost efficiencies.
  • The whitepaper details a four-step process that telcos can use to traverse the telco-to-techco journey.

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

Retrieved on: 
Monday, September 25, 2023
BIO, Intellectual property, Ontario Centre of Forensic Sciences, Partnership, CSE, University, P-1, Prior art, Medicine, University of Arkansas for Medical Sciences, Medication, MDXX, Innovation, Research, Patent Cooperation Treaty, PCT, CNS, Central nervous system, OTC, Toxicology, MDMA, Pharmacology, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.
  • “The generation of novel intellectual property is incredibly important for drug discovery companies like PharmAla.
  • This First Office Action for P-1 shows that our drug discovery pipeline yields novel, inventive molecules with significant value as neuropsychiatric therapeutics,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “Our development pipeline, which can yield new molecules appropriate for pre-clinical development, is an incredible asset for PharmAla.

Gender disparities limit chances for women PhD students training to be new inventors

Retrieved on: 
Monday, August 28, 2023
Massachusetts Institute of Technology, Faculty, National academy, PNAS, Female, Probability, Doctor of Philosophy, Prior art, National Science Foundation, Copenhagen Business School, University, MIT Sloan School of Management, Woman, Innovation, Research, MIT, Chemistry, Student, Catalysis, Iran National Science Foundation, Patent, Engineering, Invention, STEM, Management, Inclusion, Nursing, Male

CAMBRIDGE, Mass., Aug. 28, 2023 /PRNewswire/ -- In the innovation economy, individuals with STEM PhDs are a critical source of human capital, with nearly 60 percent of PhDs in STEM fields— such as engineering, chemistry and biology—being employed outside of universities. These  students are increasingly contributing to commercial science through patenting. New research from MIT Sloan School of Management and Copenhagen Business School investigated the training of these PhD students to better understand the pipeline and preparation of new inventors.

Key Points: 
  • New research from MIT Sloan School of Management and Copenhagen Business School investigated the training of these PhD students to better understand the pipeline and preparation of new inventors.
  • Female PhD students in STEM fields are less likely to become new inventors during their doctoral training.
  • In their paper published in Proceedings of the National Academy of Sciences (PNAS), " Faculty as Catalysts for Training New Inventors: Differential outcomes for Male and Female PhD Students " Delgado and Murray found that PhD students' advisors play a critical role in training new inventors.
  • "Is the opportunity to become an inventor during PhD training equally available to female and male students?

Global $49.3+ Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033: Surge in Collaborations Among Organizations for Drug Development Enabled by AI - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 16, 2023
Technology, Artificial Intelligence, Communication, Drug development, Drug discovery, European Committee for Interoperable Systems, Personalized medicine, Personal Data Privacy and Security Act of 2009, Business, Privacy, Automation, NLP, Digital image processing, Organization, US, Data analysis, Medicine, Pattern recognition, Prior art, Deep learning, Artificial intelligence, Growth, AI, Medical device, Fine chemical

The "Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Automation in Drug Discovery and Development: AI technologies enable automation in drug discovery and development processes, leading to more efficient and cost-effective research and development.
  • Increasing Collaborations: Collaborations among organizations for drug development enabled by AI are on the rise, leading to advancements in precision medicine and therapies for various conditions.
  • The report delves into market dynamics, including the factors driving and restraining the AI in biopharmaceutical market.

U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)

Retrieved on: 
Tuesday, June 13, 2023
Research, General Health, Pharmaceutical, Oncology, Biometrics, Courts, Clinical Trials, Science, FDA, Health, Diabetes, Public Policy, Government, MSD, Vaccine, Patent, Prior art, MRK, United States patent law, District court, Patient, Court, Ecosystem, Douglas v. U.S. District Court ex rel Talk America, NYSE, Pharmaceutical industry, Merck

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the Patent Term Extension period for the primary patent related to BRIDION® (sugammadex).

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the Patent Term Extension period for the primary patent related to BRIDION® (sugammadex).
  • Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
  • Today’s ruling from the U.S. District Court for the District of New Jersey affirms and validates Merck’s U.S. patent protection for BRIDION through at least January 2026.
  • “Merck’s science and technology was used to develop and launch BRIDION, and we’re pleased that the Court recognized the validity of our full patent extension period granted by the Patent Office,” said Jennifer Zachary, executive vice president and general counsel, Merck.